BS_K81DR8XG
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 25.427069645203677
- age_years
- 1.441
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.601
- E2F_TARGETS+0.501
- MYC_TARGETS_V2+0.494
- G2M_CHECKPOINT+0.467
- MYC_TARGETS_V1+0.455
- HYPOXIA+0.267
- ANGIOGENESIS+0.259
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.251
- KRAS_SIGNALING_DN+0.227
- DNA_REPAIR+0.215
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.562
- INTERFERON_GAMMA_RESPONSE-0.498
- PROTEIN_SECRETION-0.403
- HEDGEHOG_SIGNALING-0.349
- COMPLEMENT-0.295
- BILE_ACID_METABOLISM-0.292
- KRAS_SIGNALING_UP-0.254
- IL6_JAK_STAT3_SIGNALING-0.244
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.238
- ALLOGRAFT_REJECTION-0.217
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-P3-A6SX-01A-11R-A34R-07 | — | — | 0.802 |
| 2 | C3L-02358 | — | cohortSQ1 | 0.784 |
| 3 | TCGA-21-1081-01A-01R-0692-07 | — | cohortSQ1 | 0.770 |
| 4 | SRR8518399 | — | E | 0.767 |
| 5 | SRR8518449 | — | E | 0.754 |
| 6 | BS_0HW7W7SD | Embryonal tumors | — | 0.743 |
| 7 | MDT-AP-0831 | Med | Medulloblastoma | 0.742 |
| 8 | MNG715 | — | — | 0.738 |
| 9 | SRR10899997 | — | — | 0.738 |
| 10 | MDT-AP-0531 | Med | Medulloblastoma | 0.735 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.601 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.501 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.494 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.467 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.455 | Inavolisib | — uncovered |
| HYPOXIA | 0.267 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.259 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.251 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.227 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.215 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.192 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.188 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.177 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.098 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.076 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.072 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.066 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.063 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.058 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.057 | Inavolisib | — uncovered |